Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions
MS Shaikh, M Faiyazuddin, MS Khan… - Frontiers in …, 2024 - frontiersin.org
Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes,
poses a significant global health threat, with severe complications observed in vulnerable …
poses a significant global health threat, with severe complications observed in vulnerable …
The Question of HIV Vaccine: Why Is a Solution Not Yet Available?
M Libera, V Caputo, G Laterza… - Journal of …, 2024 - Wiley Online Library
Ever since its discovery, human immunodeficiency virus type 1 (HIV‐1) infection has
remained a significant public health concern. The number of HIV‐1 seropositive individuals …
remained a significant public health concern. The number of HIV‐1 seropositive individuals …
[HTML][HTML] Chikungunya vaccine development, challenges, and pathway toward public health impact
C Maure, K Khazhidinov, H Kang, M Auzenbergs… - Vaccine, 2024 - Elsevier
Chikungunya is a neglected tropical disease of growing public health concern with
outbreaks in more than 114 countries in Asia, Africa, Americas, Europe, and Oceania since …
outbreaks in more than 114 countries in Asia, Africa, Americas, Europe, and Oceania since …
[HTML][HTML] Clinical Application of Adenovirus (AdV): A Comprehensive Review
M Salauddin, S Saha, MG Hossain, K Okuda… - Viruses, 2024 - mdpi.com
Adenoviruses are non-enveloped DNA viruses that cause a wide range of symptoms, from
mild infections to life-threatening diseases in a broad range of hosts. Due to the unique …
mild infections to life-threatening diseases in a broad range of hosts. Due to the unique …
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors
F Zhu, Z Lu, W Tang, G Zhao, Y Shao… - Journal for …, 2024 - pmc.ncbi.nlm.nih.gov
Background Targeting kinases presents a potential strategy for treating solid tumors;
however, the therapeutic potential of vaccines targeting kinases remains uncertain. Methods …
however, the therapeutic potential of vaccines targeting kinases remains uncertain. Methods …
Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease
N Wang, T Wang - Biotechnology Journal, 2024 - Wiley Online Library
A vaccine is a biological preparation that contains the antigen capable of stimulating the
immune system to form the defense against pathogens. Vaccine development often …
immune system to form the defense against pathogens. Vaccine development often …
mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions
R Okuyama - Vaccines, 2023 - mdpi.com
New technological platforms, such as mRNA and adenoviral vector vaccines, have been
utilized to develop coronavirus disease 2019 (COVID-19) vaccines. These new modalities …
utilized to develop coronavirus disease 2019 (COVID-19) vaccines. These new modalities …
The systemic capillary leak syndrome following COVID-19 vaccine
C Zhao, R Xue, K Zhao, R Lei, M Zhao… - Human Vaccines & …, 2024 - Taylor & Francis
The COVID-19 outbreak has been declared the sixth Public Health Emergency of
International Concern certified by the World Health Organization. With the extensive …
International Concern certified by the World Health Organization. With the extensive …
Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein
Virus-like particles (VLPs) are an established vaccine platform and can be strong
immunogens capable of eliciting both humoral and cellular immune responses against a …
immunogens capable of eliciting both humoral and cellular immune responses against a …
Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
J Kim, C Kim, JA Lee, SJ Lee, KH Lee, JH Kim, JY Ahn… - Vaccines, 2023 - mdpi.com
This study investigated the immunogenicity of, and reactogenicity to, the ChAdOx1 nCoV-19
vaccine according to pre-existing adenovirus immunity. Individuals scheduled for COVID-19 …
vaccine according to pre-existing adenovirus immunity. Individuals scheduled for COVID-19 …